BioSpace News Archive

Mr. Shin will lead the Company’s recently announced national rollout of ZanthoSyn to the more than 3,000 corporate stores across the U.S. owned and operated by GNC.

Thermo Fisher Scientific’s Ion Torrent Oncomine Myeloid Research Assay interrogates DNA mutations, RNA fusion transcripts and gene expression levels associated with myeloid cancers in a single run, yielding results in 2-3 days.

In this role, Dr. Walsh will direct and manage the N&I Medical Affairs team to develop and implement plans for Rebif and our products in development, both in the US and in collaboration with Global Medical Affairs.

Updated preliminary results in a subgroup analysis of 57 efficacy evaluable patients with HER2-positive metastatic breast cancer pre-treated with ado-trastuzumab emtansine showed that DS-8201 demonstrated a confirmed overall response rate of 61.4 percent and a disease control rate of 94.7 percent.

Cantel Medical today announced financial results for its first quarter ended October 31, 2017.

Effective January 1, 2018, providers will receive increased payments from Medicare for the StimRouter implant procedure, making the device an even more viable pain management option for patients and physicians nationwide.

The Kerastem therapy is a one-time treatment that utilizes adipose derived regenerative cells combined with purified fat delivered to the affected area of scalp.

The Phase 2 data were presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) being held December 5-9, 2017 in San Antonio, Texas.

Seattle Genetics announced updated data from an ongoing phase 1 clinical trial evaluating ladiratuzumab vedotin in patients with metastatic triple negative breast cancer (TNBC) at the 2017 San Antonio Breast Cancer Symposium (SABCS), taking place December 5-9, 2017.

Syros announced that new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor currently in a Phase 1 clinical trial in advanced solid tumors, demonstrate anti-tumor activity across a broad panel of breast cancer cell lines and point to potential biomarkers predictive of response.